Afshin Namdar

Edmonton, AB, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15.

TGFb signaling instructs a conserved fibrosis-associated cell state marked by LRRC15.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: May 20, 2026

Cytosolic DNA structures produced by mismatch repair deficiency coordinate anti-tumor immunity in colorectal cancer.

Cytosolic DNA structures produced by mismatch repair deficiency coordinate anti-tumor immunity in colorectal cancer.

Journal: Cell reports

Published: August 06, 2025

The role of autophagy in cancer: from molecular mechanism to therapeutic window.

The role of autophagy in cancer: from molecular mechanism to therapeutic window.

Journal: Frontiers in immunology

Published: November 14, 2024

Immunomodulatory effect of CD71+ erythroid cells in patients with kidney failure.

Immunomodulatory effect of CD71+ erythroid cells in patients with kidney failure.

Journal: BMC nephrology

Published: September 05, 2024

Retraction notice to "Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib" [Life Sci. 259 (2020) 118150].

Retraction notice to "Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib" [Life Sci. 259 (2020) 118150].

Journal: Life sciences

Published: June 07, 2024

Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240].

Corrigendum to "Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy" [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240].

Journal: Nanomedicine : nanotechnology, biology, and medicine

Published: May 11, 2023

Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions.

Targeting the CTLA-4/B7 axes in glioblastoma: preclinical evidence and clinical interventions.

Journal: Expert opinion on therapeutic targets

Published: December 17, 2022

Retraction Note: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.

Retraction Note: Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.

Journal: Pharmaceutical research

Published: November 12, 2022

The prognostic and therapeutic potential of HO-1 in leukemia and MDS.

The prognostic and therapeutic potential of HO-1 in leukemia and MDS.

Journal: Cell communication and signaling : CCS

Published: August 23, 2022

Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma.

Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma.

Journal: Current oncology (Toronto, Ont.)

Published: January 19, 2022

Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10.

Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10.

Journal: The Journal of experimental medicine

Published: January 13, 2021

EP4 receptor as a novel promising therapeutic target in colon cancer.

EP4 receptor as a novel promising therapeutic target in colon cancer.

Journal: Pathology, research and practice

Published: August 11, 2020

Showing 1-12 of 49

Last Updated: 09/26/2026